Medicare pays $1,938.01 per EsoGuard test, but coverage is still case by case

What happened

On 12 November 2026, Lucid Diagnostics Inc. said Medicare has begun paying claims for its EsoGuard test at $1,938.01 per test. The company describes this as the full fee schedule rate. It also reported record October volume. The figures come from an exhibit to a US Securities and Exchange Commission filing, so they are company-reported and not confirmed by Medicare.

The record contains a crucial qualifier. Coverage is being granted case by case, while a broader MolDX reconsideration remains pending. The records do not say how many claims have been paid, how many were denied, or when the reconsideration will conclude. The October volume figure was not provided in absolute terms either, so the scale of the increase cannot be assessed from what is available.

Why it matters for market access

For a diagnostics developer, a published price is not the same as reliable reimbursement. What teams should track is the share of submitted claims that are paid at that rate, how quickly, and whether payment holds on appeal or review. Lucid's statement shows payment is occurring at the full rate. It does not show that coverage is predictable.

Case-by-case payment generally means each claim, or each patient scenario, is judged on its own file. That makes revenue harder to forecast and puts a heavy documentation burden on the laboratory and ordering clinicians. It also leaves open the risk of inconsistent outcomes across claims. A formal coverage position resolves that by setting criteria in advance. Until the MolDX reconsideration is decided, no such position exists in the record.

The regulatory and policy context

MolDX is a Medicare programme used to assess molecular diagnostic tests, and its technical assessments carry weight with the Medicare contractors that process claims. A reconsideration is a request to revisit an earlier determination. Its outcome would shape coverage more broadly than any individual paid claim. The records do not state what the original decision was, what evidence is under review or what the timetable is. Those are not yet known from the material available here.

This is why the two facts in Lucid's statement should be read together. Payment at the full rate is a positive operational signal. A pending reconsideration means the underlying coverage question remains open. Commercial payers often look to Medicare decisions when setting their own policies, but nothing in the records indicates how private insurers are treating the test, so that point should not be assumed.

Wider diagnostics context: evidence and data quality

Other items in this week's feed do not bear directly on EsoGuard, but they show what payers and HTA bodies weigh when pricing diagnostics. On 10 November, Dutch inspectorate IGJ relayed a bioMérieux field safety notice about an increased risk of false positive KPC resistance gene results on certain kit lots of three BIOFIRE panels. It is a reminder that analytical performance and lot-level quality can become reimbursement issues, because payers want confidence that a test result reliably changes patient management. It says nothing about EsoGuard's performance.

In Europe, device-data infrastructure is also still moving. Slovakia's ŠÚKL has cancelled the original deadlines for submitting data to match EUDAMED with its national device database, with next steps set out in a separate document. For companies selling diagnostics across the EU, registration and data alignment remain a moving target, which matters for tender eligibility and national listing. The record gives no detail on the new timetable.

What to watch

The first item is the MolDX reconsideration outcome and its timing, which would turn case-by-case payment into a rule or leave it as an exception. The second is whether Lucid or Medicare provides detail on claim volumes, denial rates and appeals; the current record offers none. The third is whether later disclosures from the company show the $1,938.01 rate holding across successive months of billing.

For comparison, teams assessing other diagnostics should note the pattern: early payment wins can precede a coverage policy, and the policy is what sustains the revenue. Until it arrives, treat the payment as encouraging but unproven.